US6852508B1
(en)
|
1997-02-28 |
2005-02-08 |
Genetics Institute, Llc |
Chemokine with amino-terminal modifications
|
US6100387A
(en)
*
|
1997-02-28 |
2000-08-08 |
Genetics Institute, Inc. |
Chimeric polypeptides containing chemokine domains
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
CA2341029A1
(en)
*
|
1998-08-17 |
2000-02-24 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
US7488590B2
(en)
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
AU773891C
(en)
|
1998-10-23 |
2005-02-17 |
Kirin-Amgen Inc. |
Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity
|
US6660843B1
(en)
†
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
GB9824632D0
(en)
*
|
1998-11-10 |
1999-01-06 |
Celltech Therapeutics Ltd |
Biological compounds
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
ES2694002T3
(es)
*
|
1999-01-15 |
2018-12-17 |
Genentech, Inc. |
Polipéptido que comprende una región Fc de IgG1 humana variante
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
GB9908263D0
(en)
*
|
1999-04-13 |
1999-06-02 |
Binding Site The Limited |
Eliciting improved immune responses
|
US7291714B1
(en)
|
1999-06-30 |
2007-11-06 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US6808902B1
(en)
|
1999-11-12 |
2004-10-26 |
Amgen Inc. |
Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
|
WO2002043660A2
(en)
|
2000-11-28 |
2002-06-06 |
Mediummune, Inc |
Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
|
US7229619B1
(en)
|
2000-11-28 |
2007-06-12 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
CA2407083A1
(en)
|
2000-04-21 |
2001-11-01 |
Amgen Inc. |
Apo-ai/aii peptide derivatives
|
US6667300B2
(en)
|
2000-04-25 |
2003-12-23 |
Icos Corporation |
Inhibitors of human phosphatidylinositol 3-kinase delta
|
US6677136B2
(en)
*
|
2000-05-03 |
2004-01-13 |
Amgen Inc. |
Glucagon antagonists
|
CA2408617A1
(en)
|
2000-05-12 |
2001-11-22 |
Amgen Inc. |
Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
|
US6818216B2
(en)
|
2000-11-28 |
2004-11-16 |
Medimmune, Inc. |
Anti-RSV antibodies
|
US6855493B2
(en)
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US7179900B2
(en)
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
AU2011253690C1
(en)
*
|
2000-12-12 |
2018-01-18 |
Board Of Regents, The University Of Texas System |
Molecules with extended half-lives, compositions and uses thereof
|
US7658921B2
(en)
|
2000-12-12 |
2010-02-09 |
Medimmune, Llc |
Molecules with extended half-lives, compositions and uses thereof
|
AU2008201419C1
(en)
*
|
2000-12-12 |
2018-01-18 |
Board Of Regents, The University Of Texas System |
Molecules with extended half-lives, compositions and uses thereof
|
DK1355919T3
(da)
|
2000-12-12 |
2011-03-14 |
Medimmune Llc |
Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
US7256257B2
(en)
|
2001-04-30 |
2007-08-14 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
MXPA03010210A
(es)
|
2001-05-11 |
2004-03-10 |
Amgen Inc |
Peptidos y moleculas relacionadas que se enlazan a tall-1.
|
US7332474B2
(en)
|
2001-10-11 |
2008-02-19 |
Amgen Inc. |
Peptides and related compounds having thrombopoietic activity
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US8093357B2
(en)
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
CA2485373A1
(en)
|
2002-05-10 |
2003-11-20 |
Medimmune, Inc. |
Epha2 monoclonal antibodies and methods of use thereof
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
AU2003263964C1
(en)
|
2002-07-31 |
2010-08-19 |
Seagen Inc. |
Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
|
US8187593B2
(en)
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8530627B2
(en)
|
2002-08-14 |
2013-09-10 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8946387B2
(en)
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US20040136992A1
(en)
|
2002-08-28 |
2004-07-15 |
Burton Paul B. J. |
Compositions and method for treating cardiovascular disease
|
US6919426B2
(en)
|
2002-09-19 |
2005-07-19 |
Amgen Inc. |
Peptides and related molecules that modulate nerve growth factor activity
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7365168B2
(en)
|
2002-10-15 |
2008-04-29 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7217798B2
(en)
|
2003-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of Fc-fusion protein serum half-lives by mutagenesis
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
WO2004063351A2
(en)
|
2003-01-09 |
2004-07-29 |
Macrogenics, Inc. |
IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
JP4685764B2
(ja)
*
|
2003-04-10 |
2011-05-18 |
アボット バイオセラピューティクス コーポレイション |
変異誘発による抗体のFcRn結合親和力又は血清半減期の改変
|
KR20120035234A
(ko)
|
2003-04-11 |
2012-04-13 |
메디뮨 엘엘씨 |
재조합 il?9 항체 및 그의 용도
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
EP2298347B1
(en)
|
2003-05-06 |
2015-09-30 |
Biogen Hemophilia Inc. |
Clotting factor chimeric proteins for treatment of a hemostatic disorder
|
JP2007500132A
(ja)
|
2003-07-25 |
2007-01-11 |
アムジェン インコーポレイテッド |
Ldcamのアンタゴニストおよびアゴニスト、並びにその使用法
|
CN1871259A
(zh)
|
2003-08-22 |
2006-11-29 |
比奥根艾迪克Ma公司 |
具有改变的效应物功能的经改进的抗体和制备它的方法
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
WO2005044188A2
(en)
|
2003-10-27 |
2005-05-19 |
Amgen Inc. |
Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
|
SI1725249T1
(sl)
|
2003-11-06 |
2014-04-30 |
Seattle Genetics, Inc. |
Spojine monometilvalina, sposobne konjugacije na ligande
|
CN103212084B
(zh)
|
2003-11-13 |
2018-07-13 |
韩美科学株式会社 |
含有免疫球蛋白fc区作为载体的药物组合物
|
KR101135244B1
(ko)
|
2007-11-29 |
2012-04-24 |
한미사이언스 주식회사 |
인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
|
US7371381B2
(en)
|
2003-12-12 |
2008-05-13 |
Amgen Inc. |
Anti-galanin antibodies and uses thereof
|
PT2311873T
(pt)
|
2004-01-07 |
2018-11-20 |
Novartis Vaccines & Diagnostics Inc |
Anticorpo monoclonal específico para m-csf e respetivos usos
|
WO2005070967A2
(en)
|
2004-01-22 |
2005-08-04 |
Merck Patent Gmbh |
Anti-cancer antibodies with reduced complement fixation
|
JP2008504012A
(ja)
|
2004-01-28 |
2008-02-14 |
シントニックス・ファーマシューティカルズ・インコーポレーテッド |
不妊治療のためのへテロ二量体卵胞刺激ホルモン−Fc(FSH−Fc)融合タンパク質
|
WO2005110474A2
(en)
|
2004-05-10 |
2005-11-24 |
Macrogenics, Inc. |
HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
ES2605792T3
(es)
|
2004-05-13 |
2017-03-16 |
Icos Corporation |
Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
|
MXPA06014684A
(es)
|
2004-06-18 |
2007-02-12 |
Ambrx Inc |
Novedosos polipeptidos de enlace antigeno y sus usos.
|
EP1773400A2
(en)
|
2004-07-08 |
2007-04-18 |
Amgen Inc. |
Therapeutic peptides
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
RS20070027A
(en)
|
2004-07-26 |
2008-11-28 |
Biogen Idec Ma Inc., |
Anti-cd154 antibodies
|
CA2573192C
(en)
|
2004-08-04 |
2013-09-10 |
Applied Molecular Evolution Inc. |
Variant fc regions
|
AU2005286770A1
(en)
|
2004-09-21 |
2006-03-30 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
CA2585717A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
CA2586909A1
(en)
|
2004-11-12 |
2006-12-14 |
Seattle Genetics, Inc. |
Auristatins having an aminobenzoic acid unit at the n terminus
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
EP2845865A1
(en)
|
2004-11-12 |
2015-03-11 |
Xencor Inc. |
Fc variants with altered binding to FcRn
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
DE602006003695D1
(de)
|
2005-01-05 |
2009-01-02 |
F Star Biotech Forsch & Entw |
Synthetische Immunoglobulindomänen mit in Regionen des Moleküls, die sich von den die Komplementarität bestimmenden Bereichen unterscheiden, modifizierten Bindeeigenschaften
|
KR100754667B1
(ko)
|
2005-04-08 |
2007-09-03 |
한미약품 주식회사 |
비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
EP1868650B1
(en)
|
2005-04-15 |
2018-10-03 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US11254748B2
(en)
|
2005-04-15 |
2022-02-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US7833979B2
(en)
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
EP2301969B1
(en)
|
2005-05-06 |
2015-12-23 |
ZymoGenetics, Inc. |
IL-31 monoclonal antibodies and methods of use
|
SI2314623T1
(sl)
|
2005-06-21 |
2012-11-30 |
Xoma Technology Ltd |
IL beta vezavna protitelesa in njihovi fragmenti
|
KR20080025174A
(ko)
|
2005-06-23 |
2008-03-19 |
메디뮨 인코포레이티드 |
응집 및 단편화 프로파일이 최적화된 항체 제제
|
EP3498289A1
(en)
|
2005-07-07 |
2019-06-19 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
|
CA2616005C
(en)
|
2005-07-18 |
2015-09-22 |
Seattle Genetics, Inc. |
Beta-glucuronide-linker drug conjugates
|
EP2311876A3
(en)
|
2005-07-28 |
2011-04-27 |
Novartis AG |
M-CSF-specific monoclonal antibody and uses thereof
|
ES2526811T3
(es)
|
2005-08-10 |
2015-01-15 |
Macrogenics, Inc. |
Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
DK1931709T3
(en)
|
2005-10-03 |
2017-03-13 |
Xencor Inc |
FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
|
CA2625998C
(en)
|
2005-10-06 |
2015-12-01 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
CA2626082C
(en)
|
2005-10-13 |
2017-04-11 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
TW200732350A
(en)
|
2005-10-21 |
2007-09-01 |
Amgen Inc |
Methods for generating monovalent IgG
|
EP2567973B1
(en)
|
2005-11-28 |
2014-05-14 |
Zymogenetics, Inc. |
IL-21 antagonists
|
AU2006326937B2
(en)
|
2005-12-20 |
2012-01-19 |
Cephalon Australia Pty Ltd |
Anti-inflammatory dAb
|
US9012605B2
(en)
|
2006-01-23 |
2015-04-21 |
Amgen Inc. |
Crystalline polypeptides
|
WO2007087673A1
(en)
|
2006-02-01 |
2007-08-09 |
Arana Therapeutics Limited |
Domain antibody construct
|
JP2009529915A
(ja)
|
2006-03-20 |
2009-08-27 |
ゾーマ テクノロジー リミテッド |
ガストリン物質に対して特異的なヒト抗体および方法
|
JP5624276B2
(ja)
|
2006-03-31 |
2014-11-12 |
中外製薬株式会社 |
抗体の血中動態を制御する方法
|
US9283260B2
(en)
|
2006-04-21 |
2016-03-15 |
Amgen Inc. |
Lyophilized therapeutic peptibody formulations
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
AU2007244683A1
(en)
|
2006-04-27 |
2007-11-08 |
Pikamab, Inc. |
Methods and compositions for antibody therapy
|
US7786270B2
(en)
|
2006-05-26 |
2010-08-31 |
Macrogenics, Inc. |
Humanized FcγRIIB-specific antibodies and methods of use thereof
|
SG177907A1
(en)
|
2006-06-14 |
2012-02-28 |
Macrogenics Inc |
Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
|
US7981425B2
(en)
|
2006-06-19 |
2011-07-19 |
Amgen Inc. |
Thrombopoietic compounds
|
US7932055B2
(en)
|
2006-06-22 |
2011-04-26 |
Novo Nordisk A/S |
Soluble heterodimeric CD94/NKG2 receptors fusion proteins
|
CA2656224C
(en)
|
2006-06-26 |
2018-01-09 |
Macrogenics, Inc. |
Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
|
JP5764290B2
(ja)
|
2006-06-26 |
2015-08-19 |
マクロジェニクス,インコーポレーテッド |
FcγRIIB特異的抗体およびその使用法
|
EP2037928B1
(en)
|
2006-06-26 |
2012-01-11 |
Amgen Inc. |
Methods for treating atherosclerosis
|
AT503902B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von immunglobulinen
|
AT503861B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von t-zell-rezeptoren
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
ES2746925T3
(es)
|
2006-08-03 |
2020-03-09 |
Medimmune Ltd |
Anticuerpos dirigidos hacia alfaVbeta6 y uso de los mismos
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
WO2008019290A2
(en)
|
2006-08-04 |
2008-02-14 |
Astrazeneca Ab |
Human antibodies to erbb 2
|
CN101626783A
(zh)
|
2006-08-04 |
2010-01-13 |
诺华有限公司 |
Ephb3-特异性抗体和其应用
|
ES2457072T3
(es)
|
2006-08-14 |
2014-04-24 |
Xencor, Inc. |
Anticuerpos optimizados que seleccionan como diana CD19
|
EP2059535B1
(en)
|
2006-08-18 |
2013-11-06 |
Novartis AG |
Prlr-specific antibody and uses thereof
|
MX2009002151A
(es)
|
2006-08-28 |
2009-07-03 |
Kirin Pharma Kk |
Anticuerpos monoclonales humanos especificos para light humano antagonistas.
|
ES2519375T3
(es)
|
2006-09-01 |
2014-11-06 |
Zymogenetics, Inc. |
Anticuerpos monoclonales IL-31 y procedimientos de uso
|
CA2660795C
(en)
|
2006-09-18 |
2014-11-18 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
US20100143254A1
(en)
|
2006-10-16 |
2010-06-10 |
Medimmune, Llc |
Molecules with reduced half-lives, compositions and uses thereof
|
US7825093B2
(en)
|
2006-10-25 |
2010-11-02 |
Amgen Inc. |
Methods of using OSK1 peptide analogs
|
HU0700534D0
(en)
|
2006-11-24 |
2007-10-29 |
Mezoegazdasagi Biotechnologiai |
Transgenic animal with enhanced immune response and method for the preparation thereof
|
PL2099823T5
(pl)
|
2006-12-01 |
2023-02-20 |
Seagen Inc. |
Wariant środków wiążących cel i jego zastosowania
|
WO2008070780A1
(en)
|
2006-12-07 |
2008-06-12 |
Novartis Ag |
Antagonist antibodies against ephb3
|
WO2008140603A2
(en)
|
2006-12-08 |
2008-11-20 |
Macrogenics, Inc. |
METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
|
AU2007333635B2
(en)
|
2006-12-20 |
2014-02-20 |
Xoma (Us) Llc |
Treatment of IL-1-beta related diseases
|
JP2008169195A
(ja)
|
2007-01-05 |
2008-07-24 |
Hanmi Pharmaceutical Co Ltd |
キャリア物質を用いたインスリン分泌ペプチド薬物結合体
|
EP2077859A4
(en)
|
2007-03-30 |
2010-11-24 |
Medimmune Llc |
ANTIBODY FORMULATION
|
ES2540807T3
(es)
|
2007-05-04 |
2015-07-13 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa |
Dominios variables de anticuerpos de conejo modificados por ingeniería genética y usos de los mismos
|
PT2160401E
(pt)
|
2007-05-11 |
2014-10-30 |
Altor Bioscience Corp |
Moléculas de fusão e variantes de il-15
|
NO3072525T3
(ja)
|
2007-05-14 |
2018-06-30 |
|
|
CA2687141C
(en)
|
2007-05-22 |
2014-04-01 |
Amgen Inc. |
Compositions and methods for producing bioactive fusion proteins
|
ES2659517T3
(es)
|
2007-05-30 |
2018-03-16 |
Xencor, Inc. |
Métodos y composiciones para inhibir células que expresan CD32B
|
EP1997830A1
(en)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV specific binding molecules and means for producing them
|
ES2627223T3
(es)
|
2007-06-26 |
2017-07-27 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Presentación de agentes de unión
|
WO2009014708A2
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
DK2181190T3
(da)
|
2007-07-26 |
2014-03-31 |
Amgen Inc |
Modificerede lecithin-kolesterol-acyltransferase-enzymer
|
CN101952312A
(zh)
|
2007-07-31 |
2011-01-19 |
米迪缪尼有限公司 |
多特异性表位结合蛋白及其应用
|
PE20140196A1
(es)
|
2007-08-09 |
2014-03-19 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
NO2195023T3
(ja)
|
2007-08-29 |
2018-08-04 |
|
|
EP3689912A1
(en)
|
2007-09-26 |
2020-08-05 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substitution in cdr
|
ES2622460T3
(es)
|
2007-09-26 |
2017-07-06 |
Ucb Biopharma Sprl |
Fusiones de anticuerpos con doble especificidad
|
EP2050764A1
(en)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
AU2008333131B2
(en)
|
2007-12-07 |
2013-10-24 |
Merck Serono S/A |
Humanized antibody molecules specific for IL-31
|
DK2217268T3
(en)
|
2007-12-07 |
2016-08-15 |
Zymogenetics Inc |
MONOCLONAL ANTI-HUMAN IL-21 ANTIBODIES
|
WO2009117030A2
(en)
|
2007-12-19 |
2009-09-24 |
Macrogenics, Inc. |
Improved compositions for the prevention and treatment of smallpox
|
MX2010006823A
(es)
|
2007-12-20 |
2010-09-30 |
Xoma Technology Ltd |
Metodos para el tratamiento de la gota.
|
US8414893B2
(en)
|
2007-12-21 |
2013-04-09 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
EP3575317A1
(en)
|
2007-12-26 |
2019-12-04 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
MX2010007767A
(es)
|
2008-01-18 |
2010-08-09 |
Medimmune Llc |
Anticuerpos manipulados con cisteina para conjugacion especifica de sitio.
|
US8609105B2
(en)
|
2008-03-18 |
2013-12-17 |
Seattle Genetics, Inc. |
Auristatin drug linker conjugates
|
ES2589912T3
(es)
|
2008-04-02 |
2016-11-17 |
Macrogenics, Inc. |
Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
|
PL2247304T3
(pl)
|
2008-04-02 |
2017-01-31 |
Macrogenics, Inc. |
Przeciwciała specyficzne wobec HER2/neu oraz sposoby ich zastosowania
|
TWI564021B
(zh)
|
2008-04-11 |
2017-01-01 |
Chugai Pharmaceutical Co Ltd |
Repeated binding of antigen to antigen binding molecules
|
WO2009131702A2
(en)
*
|
2008-04-25 |
2009-10-29 |
Dyax Corp. |
Antibodies against fcrn and use thereof
|
EP2113255A1
(en)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Cytotoxic immunoglobulin
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
EP2671891A3
(en)
|
2008-06-27 |
2014-03-05 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
MX356218B
(es)
|
2008-08-05 |
2018-05-18 |
Novartis Ag |
Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5.
|
JP5611210B2
(ja)
|
2008-09-07 |
2014-10-22 |
グリコネックス インコーポレイテッド |
抗拡張i型スフィンゴ糖脂質抗体、その誘導体および使用
|
WO2010032060A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune Llc |
Antibodies directed to dll4 and uses thereof
|
CN110317272A
(zh)
*
|
2008-10-14 |
2019-10-11 |
霍夫曼-拉罗奇有限公司 |
免疫球蛋白变体及其用途
|
BRPI0921845A2
(pt)
|
2008-11-12 |
2019-09-17 |
Medimmune Llc |
formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
|
US9492449B2
(en)
|
2008-11-13 |
2016-11-15 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
CN104042618B
(zh)
|
2008-11-13 |
2018-02-16 |
吉利德卡利斯托加公司 |
恶性血液病的治疗
|
US8775090B2
(en)
|
2008-12-12 |
2014-07-08 |
Medimmune, Llc |
Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
|
US20120114667A1
(en)
|
2008-12-23 |
2012-05-10 |
Medimmune Limited |
TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
|
US8852608B2
(en)
|
2009-02-02 |
2014-10-07 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
EP3385279B1
(en)
|
2009-03-20 |
2020-02-26 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
AU2010229968A1
(en)
|
2009-03-24 |
2011-10-13 |
Gilead Calistoga Llc |
Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
|
EA201101507A1
(ru)
|
2009-04-20 |
2012-05-30 |
Гилеад Калистога Ллс. |
Способы лечения солидных опухолей
|
CN106188295A
(zh)
|
2009-04-20 |
2016-12-07 |
牛津生物疗法有限公司 |
特异于钙粘素‑17的抗体
|
CA2759333A1
(en)
|
2009-04-22 |
2010-10-28 |
Merck Patent Gmbh |
Antibody fusion proteins with modified fcrn binding sites
|
US20120052069A1
(en)
|
2009-05-05 |
2012-03-01 |
Amgen Inc |
Fgf21 mutants and uses thereof
|
SG10201402038WA
(en)
|
2009-05-05 |
2014-07-30 |
Amgen Inc |
FGF21 Mutants And Uses Thereof
|
ES2548030T3
(es)
|
2009-06-01 |
2015-10-13 |
Medimmune, Llc |
Moléculas con semividas prolongadas y usos de las mismas
|
EP2443137B1
(en)
|
2009-06-15 |
2015-05-20 |
Biokine Therapeutics Ltd. |
Novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer
|
EP2442824A2
(en)
|
2009-06-19 |
2012-04-25 |
MedImmune, LLC |
Protease variants
|
EP2711018A1
(en)
|
2009-06-22 |
2014-03-26 |
MedImmune, LLC |
Engineered Fc regions for site-specific conjugation
|
EP2456443A1
(en)
|
2009-07-21 |
2012-05-30 |
Gilead Calistoga LLC |
Treatment of liver disorders with pi3k inhibitors
|
US8840889B2
(en)
|
2009-08-13 |
2014-09-23 |
The Johns Hopkins University |
Methods of modulating immune function
|
CA2770737C
(en)
|
2009-08-13 |
2020-05-12 |
Crucell Holland B.V. |
Antibodies against human respiratory syncytial virus (rsv) and methods of use
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
US9885711B2
(en)
|
2009-09-25 |
2018-02-06 |
Xoma Technology Ltd. |
Screening methods
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
SI2486141T1
(en)
|
2009-10-07 |
2018-06-29 |
Macrogenics, Inc. |
FC REGION-CONTAINING POLYPETHYDE, AFFECTING A BETTERED EFFECTORAL FUNCTION, BY CHANGES IN THE SCOPE OF FUKOZILATION AND METHODS FOR THEIR USE
|
US20120231004A1
(en)
|
2009-10-13 |
2012-09-13 |
Oxford Biotherapeutic Ltd. |
Antibodies
|
WO2011056073A2
(en)
|
2009-11-04 |
2011-05-12 |
Erasmus University Medical Center Rotterdam |
Novel compounds for modulating neovascularisation and methods of treatment using these compounds
|
MX2012005864A
(es)
|
2009-11-20 |
2012-08-31 |
Amgen Inc |
Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas.
|
MX343747B
(es)
|
2009-11-24 |
2016-11-22 |
Medimmune Ltd |
Agentes de union diana contra b7-h1.
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
KR101312829B1
(ko)
|
2009-12-30 |
2013-09-27 |
한화엘앤씨 주식회사 |
HO-1 유전자 및 TNFR1-Fc 유전자를 동시에 발현하는 형질전환 돼지 및 그의 제조 방법
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
NZ701539A
(en)
|
2010-03-04 |
2015-04-24 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
AR081066A1
(es)
|
2010-04-02 |
2012-06-06 |
Hanmi Holdings Co Ltd |
Conjugado de insulina donde se usa un fragmento de inmunoglobulina
|
AR081755A1
(es)
|
2010-04-02 |
2012-10-17 |
Hanmi Holdings Co Ltd |
Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo
|
AR080993A1
(es)
|
2010-04-02 |
2012-05-30 |
Hanmi Holdings Co Ltd |
Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
|
EP2556086B1
(en)
|
2010-04-09 |
2015-03-04 |
Amgen Inc. |
Btnl9 proteins, nucleic acids, and antibodies and uses thereof
|
MX2012011986A
(es)
|
2010-04-15 |
2013-03-05 |
Amgen Inc |
RECEPTOR FGF HUMANO Y PROTEINAS ENLAZADAS A ß-KLOTHO.
|
BR112012028326A2
(pt)
|
2010-05-06 |
2017-03-21 |
Novartis Ag |
anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos
|
US9428583B2
(en)
|
2010-05-06 |
2016-08-30 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
|
BR112012030179A8
(pt)
|
2010-05-27 |
2023-03-14 |
Merck Sharp & Dohme |
Polipeptídeo contendo fc
|
CN103140237A
(zh)
|
2010-07-09 |
2013-06-05 |
比奥根艾迪克依蒙菲利亚公司 |
因子ix多肽及其使用方法
|
NZ703035A
(en)
|
2010-07-09 |
2016-06-24 |
Crucell Holland Bv |
Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
|
KR101382593B1
(ko)
|
2010-07-21 |
2014-04-10 |
한미사이언스 주식회사 |
신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
|
MX339622B
(es)
|
2010-08-02 |
2016-06-02 |
Macrogenics Inc |
Diacuerpos covalentes y sus usos.
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
ME02637B
(me)
|
2010-08-20 |
2017-06-20 |
Novartis Ag |
Antitela za receptor 3 faktora rasta epiderma (her3)
|
SG10201506782XA
(en)
|
2010-08-27 |
2015-10-29 |
Stem Centrx Inc |
Notum protein modulators and methods of use
|
CN106620693A
(zh)
|
2010-09-03 |
2017-05-10 |
艾伯维施特姆森特克斯有限责任公司 |
新型调节剂及使用方法
|
US11053299B2
(en)
|
2010-09-21 |
2021-07-06 |
Immunity Bio, Inc. |
Superkine
|
JP6251570B2
(ja)
|
2010-09-21 |
2017-12-20 |
アルター・バイオサイエンス・コーポレーション |
多量体il−15可溶性融合分子並びにその製造及び使用方法
|
JP6159660B2
(ja)
|
2010-09-22 |
2017-07-05 |
アムジエン・インコーポレーテツド |
担体としての免疫グロブリンおよびその使用
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
RS59589B1
(sr)
|
2010-11-05 |
2019-12-31 |
Zymeworks Inc |
Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
|
US9023791B2
(en)
|
2010-11-19 |
2015-05-05 |
Novartis Ag |
Fibroblast growth factor 21 mutations
|
EP2643353A1
(en)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispecific molecules
|
MX365235B
(es)
|
2010-11-30 |
2019-05-28 |
Chugai Pharmaceutical Co Ltd |
Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
|
RU2592672C9
(ru)
|
2010-12-08 |
2016-11-27 |
СтемСентРкс, Инк. |
Новые модуляторы и способы их применения
|
PT2654790T
(pt)
|
2010-12-22 |
2019-05-16 |
Teva Pharmaceuticals Australia Pty Ltd |
Anticorpo modificado com semivida melhorada
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
KR101276801B1
(ko)
|
2011-01-21 |
2013-06-19 |
한화엘앤씨 주식회사 |
sTNFR1-Fc 유전자를 발현하는 형질전환 돼지 및 이의 용도
|
WO2012103165A2
(en)
|
2011-01-26 |
2012-08-02 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
US20140093496A1
(en)
|
2011-02-25 |
2014-04-03 |
Chugai Seiyaku Kabushiki Kaisha |
Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
|
KR20140145947A
(ko)
|
2011-03-16 |
2014-12-24 |
암젠 인크 |
Nav1.3과 nav1.7의 유효한 선별적 저해제
|
EP2686014A1
(en)
|
2011-03-16 |
2014-01-22 |
Sanofi |
Uses of a dual v region antibody-like protein
|
KR20160044598A
(ko)
|
2011-03-29 |
2016-04-25 |
로슈 글리카트 아게 |
항체 Fc 변이체
|
EP3415528B1
(en)
|
2011-04-13 |
2021-05-26 |
Bristol-Myers Squibb Company |
Fc fusion proteins comprising novel linkers or arrangements
|
JP6145088B2
(ja)
|
2011-05-21 |
2017-06-07 |
マクロジェニクス,インコーポレーテッド |
脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用
|
AU2012258907A1
(en)
|
2011-05-25 |
2013-11-07 |
Merck Sharp & Dohme Corp. |
Method for preparing Fc-containing polypeptides having improved properties
|
UA113626C2
(xx)
|
2011-06-02 |
2017-02-27 |
|
Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
|
CN108424451B
(zh)
|
2011-06-03 |
2022-09-09 |
佐马技术有限公司 |
对TGF-β具有特异性的抗体
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
WO2012170742A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Treatment and prevention of cancer with hmgb1 antagonists
|
CA2838503C
(en)
|
2011-06-10 |
2020-02-18 |
Hanmi Science Co., Ltd. |
Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
PH12018501119A1
(en)
|
2011-06-17 |
2019-02-04 |
Hanmi Science Co Ltd |
A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
|
EP2726508B1
(en)
|
2011-06-28 |
2017-08-09 |
Oxford BioTherapeutics Ltd |
Antibodies to adp-ribosyl cyclase 2
|
JP2014520869A
(ja)
|
2011-07-18 |
2014-08-25 |
アルツ バイオロジクス アクティーゼルスカブ |
長期作用性で生物学的活性が有る黄体形成ホルモン(lh)化合物
|
GB201112429D0
(en)
|
2011-07-19 |
2011-08-31 |
Glaxo Group Ltd |
Antigen-binding proteins with increased FcRn binding
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
JP6284478B2
(ja)
|
2011-09-05 |
2018-02-28 |
ハンミ サイエンス カンパニー リミテッド |
インターフェロンアルファ結合体を含む癌治療用医薬組成物
|
TWI593708B
(zh)
|
2011-09-26 |
2017-08-01 |
諾華公司 |
治療代謝病症之融合蛋白質
|
TW201315742A
(zh)
|
2011-09-26 |
2013-04-16 |
Novartis Ag |
治療代謝病症之雙功能蛋白質
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
SG11201401101XA
(en)
|
2011-09-30 |
2014-08-28 |
Chugai Pharmaceutical Co Ltd |
Antigen-binding molecule for promoting loss of antigens
|
EP2760471B9
(en)
|
2011-09-30 |
2017-07-19 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides
|
US20150050269A1
(en)
|
2011-09-30 |
2015-02-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
EP2773667A1
(en)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
EP2773664A1
(en)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
WO2013067055A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
EP2773665A1
(en)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Antibodies and methods of treating cancer
|
CN104080811B
(zh)
|
2011-11-04 |
2019-09-27 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
KR20130049671A
(ko)
|
2011-11-04 |
2013-05-14 |
한미사이언스 주식회사 |
생리활성 폴리펩타이드 결합체 제조 방법
|
TW201323442A
(zh)
|
2011-11-04 |
2013-06-16 |
Novartis Ag |
低密度脂蛋白相關蛋白6(lrp6)-半衰期延長構築體
|
WO2013068571A1
(en)
|
2011-11-11 |
2013-05-16 |
Ucb Pharma S.A. |
Albumin binding antibodies and binding fragments thereof
|
BR112014012609A2
(pt)
|
2011-11-17 |
2020-10-20 |
Pfizer Inc |
peptídeos citotóxicos e conjungados de droga de anticorpo dos mesmos
|
US20150056182A1
(en)
|
2011-11-30 |
2015-02-26 |
Chugai Seiyaku Kabushiki Kaisha |
Drug containing carrier into cell for forming immune complex
|
TW201328707A
(zh)
|
2011-12-05 |
2013-07-16 |
Novartis Ag |
針對表皮生長因子受體3(her3)之區域ii之her3抗體
|
CN104159924B
(zh)
|
2011-12-05 |
2018-03-16 |
诺华股份有限公司 |
表皮生长因子受体3(her3)的抗体
|
WO2013096516A1
(en)
|
2011-12-19 |
2013-06-27 |
Xoma Technology Ltd. |
Methods for treating acne
|
CN106831985A
(zh)
|
2011-12-21 |
2017-06-13 |
诺华股份有限公司 |
用于抗体靶定p因子的组合物和方法
|
CA2859755C
(en)
|
2011-12-23 |
2021-04-20 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
KR101895047B1
(ko)
|
2011-12-30 |
2018-09-06 |
한미사이언스 주식회사 |
면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
|
JP2015509091A
(ja)
|
2012-01-09 |
2015-03-26 |
ザ スクリプス リサーチ インスティテュート |
ヒト化抗体
|
WO2013106485A2
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
WO2013126746A2
(en)
|
2012-02-24 |
2013-08-29 |
Stem Centrx, Inc. |
Novel modulators and methods of use
|
TW202015731A
(zh)
|
2012-02-24 |
2020-05-01 |
日商中外製藥股份有限公司 |
經FcγRIIB促進抗原消失之抗原結合分子
|
EA201691327A1
(ru)
|
2012-03-05 |
2017-03-31 |
Джилид Калистога Ллс |
Полиморфные формы (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она
|
AR090281A1
(es)
|
2012-03-08 |
2014-10-29 |
Hanmi Science Co Ltd |
Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
|
KR101665009B1
(ko)
|
2012-03-09 |
2016-10-11 |
한미사이언스 주식회사 |
비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
US10064951B2
(en)
|
2012-03-30 |
2018-09-04 |
Hanmi Science Co., Ltd. |
Liquid formulation of highly concentrated long-acting human growth hormone conjugate
|
WO2013169693A1
(en)
|
2012-05-09 |
2013-11-14 |
Bristol-Myers Squibb Company |
Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
|
CA2872540A1
(en)
|
2012-05-10 |
2013-11-14 |
Zymeworks Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
|
GB201208370D0
(en)
*
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Antibodies
|
JP6423340B2
(ja)
|
2012-05-15 |
2018-11-14 |
シアトル ジェネティクス,インコーポレイティド |
自己安定化リンカー結合体
|
CN104335047B
(zh)
*
|
2012-05-23 |
2017-08-15 |
弗·哈夫曼-拉罗切有限公司 |
治疗剂的选择方法
|
CA2874721A1
(en)
|
2012-05-30 |
2013-12-05 |
Tomoyuki Igawa |
Target tissue-specific antigen-binding molecule
|
DK2857419T3
(da)
|
2012-05-30 |
2021-03-29 |
Chugai Pharmaceutical Co Ltd |
Antigen-bindende molekyle til eliminering af aggregerede antigener
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
US20140004121A1
(en)
|
2012-06-27 |
2014-01-02 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
HRP20211641T1
(hr)
|
2012-07-13 |
2022-02-04 |
Roche Glycart Ag |
Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti
|
EP2875046B1
(en)
|
2012-07-19 |
2020-02-26 |
Amgen Inc. |
Human btnl3 proteins, nucleic acids, and antibodies and uses thereof
|
AR091902A1
(es)
|
2012-07-25 |
2015-03-11 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de un conjugado de insulina de accion prolongada
|
AR092862A1
(es)
|
2012-07-25 |
2015-05-06 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
|
KR101968344B1
(ko)
|
2012-07-25 |
2019-04-12 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
|
NZ630363A
(en)
|
2012-07-25 |
2018-09-28 |
Celldex Therapeutics Inc |
Anti-kit antibodies and uses thereof
|
MX371442B
(es)
|
2012-08-24 |
2020-01-30 |
Chugai Pharmaceutical Co Ltd |
VARIANTE DE LA REGION FC ESPECIFICA PARA FCyRIIB.
|
SG11201502757QA
(en)
|
2012-10-09 |
2015-05-28 |
Igenica Biotherapeutics Inc |
Anti-c16orf54 antibodies and methods of use thereof
|
KR101762047B1
(ko)
|
2012-11-05 |
2017-07-27 |
화이자 인코포레이티드 |
스플라이세오스타틴 유사체
|
KR101993393B1
(ko)
|
2012-11-06 |
2019-10-01 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
|
EA031852B1
(ru)
|
2012-11-06 |
2019-03-29 |
Ханми Фарм. Ко., Лтд. |
Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина
|
EP2917240A1
(en)
|
2012-11-07 |
2015-09-16 |
Pfizer Inc. |
Anti-notch3 antibodies and antibody-drug conjugates
|
UY35144A
(es)
|
2012-11-20 |
2014-06-30 |
Novartis Ag |
Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
US9353150B2
(en)
|
2012-12-04 |
2016-05-31 |
Massachusetts Institute Of Technology |
Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
|
MX368067B
(es)
|
2012-12-05 |
2019-09-18 |
Novartis Ag |
Composiciones y métodos para dirigir anticuerpos a la eritropoyetina (epo).
|
CN105051064A
(zh)
|
2013-01-24 |
2015-11-11 |
葛兰素史克知识产权开发有限公司 |
抗TNF-α抗原结合蛋白
|
KR102073748B1
(ko)
|
2013-01-31 |
2020-02-05 |
한미약품 주식회사 |
재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법
|
US10065987B2
(en)
|
2013-02-12 |
2018-09-04 |
Bristol-Myers Squibb Company |
High pH protein refolding methods
|
EP3744728A1
(en)
|
2013-02-12 |
2020-12-02 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
WO2014129895A1
(en)
|
2013-02-19 |
2014-08-28 |
Stichting Vu-Vumc |
Means and method for increasing the sensitivity of cancers for radiotherapy
|
CN105164159A
(zh)
|
2013-02-22 |
2015-12-16 |
施特姆森特克斯股份有限公司 |
新的抗体缀合物及其用途
|
PT2963055T
(pt)
|
2013-02-26 |
2019-07-25 |
Hanmi Pharm Ind Co Ltd |
Conugado de insulina específico ao local
|
PE20191481A1
(es)
|
2013-02-26 |
2019-10-18 |
Hanmi Pharm Ind Co Ltd |
Analogo de insulina novedoso y su uso
|
TWI647240B
(zh)
|
2013-03-05 |
2019-01-11 |
韓美藥品股份有限公司 |
生理活性多肽複合物高產率製備之改良製程
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
WO2014136114A1
(en)
|
2013-03-06 |
2014-09-12 |
Protalix Ltd. |
TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME
|
US10087232B2
(en)
|
2013-03-06 |
2018-10-02 |
Protalix Ltd. |
Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapy
|
EP2970408B1
(en)
|
2013-03-12 |
2018-01-10 |
Amgen Inc. |
Potent and selective inhibitors of nav1.7
|
EP3431592A1
(en)
|
2013-03-14 |
2019-01-23 |
Translate Bio, Inc. |
Mrna therapeutic compositions and use to treat diseases and disorders
|
JP2016514130A
(ja)
|
2013-03-14 |
2016-05-19 |
ノバルティス アーゲー |
Notch3に対する抗体
|
LT2968520T
(lt)
|
2013-03-14 |
2021-09-27 |
Macrogenics, Inc. |
Bispecifinės molekulės, kurios yra imunoreaktyvios imuninių efektorių ląstelėms, kurios ekspresuoja aktyvuojantį receptorių
|
EP2968440B1
(en)
|
2013-03-15 |
2019-06-05 |
Zymeworks Inc. |
Cytotoxic and anti-mitotic compounds, and methods of using the same
|
BR112015023084A2
(pt)
|
2013-03-15 |
2017-11-21 |
Abbvie Biotechnology Ltd |
anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira procariota e eucariota, método para a produção de um anticorpo anti-cd25 ou fragmento ligante anti-cd25, e, uso de um anticorpo anti-cd25 monoclonal de um conjugado anticorpo-droga ou de uma composição farmacêutica
|
MX2015012563A
(es)
|
2013-03-15 |
2016-10-26 |
Abbvie Biotechnology Ltd |
Anticuerpos anti-cd25 y sus usos.
|
JP6397886B2
(ja)
|
2013-03-15 |
2018-09-26 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
治療用ペプチド
|
US20140377253A1
(en)
|
2013-03-15 |
2014-12-25 |
Abbvie Biotherapeutics Inc. |
Fc variants
|
US20160051673A1
(en)
|
2013-03-29 |
2016-02-25 |
Alexion Pharmaceuticals, Inc. |
Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
|
EP3783017A1
(en)
|
2013-04-02 |
2021-02-24 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant
|
KR101895634B1
(ko)
|
2013-05-31 |
2018-09-05 |
한미약품 주식회사 |
변이된 힌지 영역을 포함하는 IgG4 Fc 단편
|
US10100123B2
(en)
|
2013-06-06 |
2018-10-16 |
Pierre Fabre Medicament |
Anti-C10orf54 antibodies and uses thereof
|
WO2014200349A1
(en)
|
2013-06-13 |
2014-12-18 |
Fast Forward Pharmaceutical B.V. |
Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
UY35620A
(es)
|
2013-06-21 |
2015-01-30 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
AR096891A1
(es)
|
2013-07-12 |
2016-02-03 |
Hanmi Pharm Ind Co Ltd |
Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
|
AR096890A1
(es)
|
2013-07-12 |
2016-02-03 |
Hanmi Pharm Ind Co Ltd |
Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
|
WO2015017146A2
(en)
|
2013-07-18 |
2015-02-05 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
CN111518199A
(zh)
|
2013-07-18 |
2020-08-11 |
图鲁斯生物科学有限责任公司 |
具有超长互补决定区的人源化抗体
|
US9340582B2
(en)
|
2013-07-25 |
2016-05-17 |
Novartis Ag |
Bioconjugates of synthetic apelin polypeptides
|
MX2016001020A
(es)
|
2013-07-25 |
2016-08-03 |
Novartis Ag |
Polipeptidos ciclicos para el tratamiento de insuficiencia cardiaca.
|
WO2015017529A2
(en)
|
2013-07-31 |
2015-02-05 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
KR20160054501A
(ko)
|
2013-08-26 |
2016-05-16 |
맵백스 테라퓨틱스, 인코포레이티드 |
시알릴-루이스 a에 대한 사람 항체 코드화 핵산
|
CN105848671B
(zh)
|
2013-08-28 |
2019-12-13 |
艾伯维施特姆森特克斯有限责任公司 |
位点特异性抗体缀合方法和组合物
|
KR20160046914A
(ko)
|
2013-08-28 |
2016-04-29 |
스템센트알엑스 인코포레이티드 |
신규한 sez6 조절물질 및 사용방법
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
BR112016006455A2
(pt)
|
2013-09-27 |
2017-08-01 |
Hanmi Pharm Ind Co Ltd |
?formulação de conjugado de hormônio de crescimento humano de ação prolongada?
|
CA2921707C
(en)
|
2013-10-15 |
2023-03-28 |
Seattle Genetics, Inc. |
Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
|
EP3057605A1
(en)
|
2013-10-18 |
2016-08-24 |
Novartis AG |
Methods of treating diabetes and related disorders
|
PE20160870A1
(es)
|
2013-11-06 |
2016-09-09 |
Abbvie Stemcentrx Llc |
Anticuerpos anti-claudina novedosos y metodos de uso
|
EP3094973B1
(en)
|
2013-11-07 |
2020-07-29 |
Diagnodus Limited |
Biomarkers
|
AU2014357292B2
(en)
|
2013-11-27 |
2020-06-25 |
Zymeworks Bc Inc. |
Bispecific antigen-binding constructs targeting HER2
|
BR112016012358A2
(pt)
|
2013-12-06 |
2017-09-26 |
Dana Farber Cancer Inst Inc |
peptídios terapêuticos
|
TWI777502B
(zh)
|
2013-12-19 |
2022-09-11 |
美商西雅圖遺傳學公司 |
與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物
|
EP3083623A1
(en)
|
2013-12-20 |
2016-10-26 |
Gilead Calistoga LLC |
Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
|
NZ736970A
(en)
|
2013-12-20 |
2018-11-30 |
Gilead Calistoga Llc |
Process methods for phosphatidylinositol 3-kinase inhibitors
|
MX368804B
(es)
|
2013-12-24 |
2019-10-17 |
Univ Texas |
Antagonistas fcrn y metodos de uso.
|
EP3086815B1
(en)
|
2013-12-27 |
2022-02-09 |
Zymeworks Inc. |
Sulfonamide-containing linkage systems for drug conjugates
|
CN110903398B
(zh)
*
|
2014-01-15 |
2023-08-15 |
豪夫迈·罗氏有限公司 |
具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
|
PE20161153A1
(es)
|
2014-01-20 |
2016-10-27 |
Hanmi Pharm Ind Co Ltd |
Insulina de accion prolongada y uso de la misma
|
US9738716B2
(en)
|
2014-01-24 |
2017-08-22 |
Ngm Biopharmaceuticals, Inc. |
Beta klotho binding proteins and methods of use thereof
|
PT3099692T
(pt)
|
2014-01-27 |
2019-05-24 |
Pfizer |
Agentes citotóxicos bifuncionais
|
KR20240036143A
(ko)
|
2014-02-17 |
2024-03-19 |
씨젠 인크. |
친수성 항체-약물 컨쥬게이트
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
CA2939006A1
(en)
|
2014-03-14 |
2015-09-17 |
Dana-Farber Cancer Institute, Inc. |
Vaccine compositions and methods for restoring nkg2d pathway function against cancers
|
WO2015152618A1
(ko)
|
2014-03-31 |
2015-10-08 |
한미약품 주식회사 |
면역글로불린 fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법
|
MX2016012873A
(es)
|
2014-04-04 |
2017-03-07 |
Bionomics Inc |
Anticuerpos humanizados que se unen al receptor 5 acoplado a proteina g que contiene repeticion rica en leucina (lgr5).
|
ES2913205T3
(es)
|
2014-05-13 |
2022-06-01 |
Bioatla Inc |
Proteínas biológicas activas condicionalmente
|
US20170267780A1
(en)
|
2014-05-16 |
2017-09-21 |
Medimmune, Llc |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
PL3148579T3
(pl)
|
2014-05-28 |
2021-07-19 |
Agenus Inc. |
Przeciwciała anty-gitr i sposoby ich zastosowania
|
AR100639A1
(es)
|
2014-05-29 |
2016-10-19 |
Hanmi Pharm Ind Co Ltd |
Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
|
TWI684458B
(zh)
|
2014-05-30 |
2020-02-11 |
南韓商韓美藥品股份有限公司 |
包含胰島素及glp-1/昇糖素雙重促效劑之治療糖尿病之組成物
|
WO2015187811A2
(en)
|
2014-06-04 |
2015-12-10 |
MabVax Therapeutics, Inc. |
Human monoclonal antibodies to ganglioside gd2
|
KR20150140177A
(ko)
|
2014-06-05 |
2015-12-15 |
한미약품 주식회사 |
단백질 및 펩타이드의 면역원성을 감소시키는 방법
|
SI3151921T1
(sl)
|
2014-06-06 |
2019-12-31 |
Bristol-Myers Squibb Company |
Protitelesa proti z glukortikoidom induciranim receptorjem za faktor nekroze tumorja(GITR) in njihova uporaba
|
CA2951391C
(en)
|
2014-06-10 |
2021-11-02 |
Amgen Inc. |
Apelin polypeptides
|
AU2015274696B2
(en)
|
2014-06-13 |
2018-09-27 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
WO2015200080A1
(en)
|
2014-06-23 |
2015-12-30 |
Novartis Ag |
Site specific protein modifications
|
EP3673915A1
(en)
|
2014-06-30 |
2020-07-01 |
Altor BioScience Corporation |
Il-15-based molecules and methods of use thereof
|
PE20170287A1
(es)
|
2014-08-07 |
2017-04-05 |
Novartis Ag |
Anticuerpos anti-proteina similar a angiopoyetina 4 y metodos de uso
|
EP3194437B1
(en)
|
2014-08-07 |
2021-01-20 |
Novartis AG |
Angiopoietin-like 4 (angptl4) antibodies and methods of use
|
WO2016036916A1
(en)
|
2014-09-03 |
2016-03-10 |
Bioatla, Llc |
Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
|
SG11201701423RA
(en)
|
2014-09-03 |
2017-03-30 |
Boehringer Ingelheim Int |
Compound targeting il-23a and tnf-alpha and uses thereof
|
TW201617368A
(zh)
|
2014-09-05 |
2016-05-16 |
史坦森特瑞斯公司 |
新穎抗mfi2抗體及使用方法
|
MX2017003247A
(es)
|
2014-09-15 |
2017-11-30 |
Amgen Inc |
Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
|
TWI802396B
(zh)
|
2014-09-16 |
2023-05-11 |
南韓商韓美藥品股份有限公司 |
長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
|
EP4029873A1
(en)
|
2014-09-17 |
2022-07-20 |
Zymeworks Inc. |
Cytotoxic and anti-mitotic compounds, and methods of using the same
|
CN107108721B
(zh)
|
2014-09-29 |
2021-09-07 |
杜克大学 |
包含hiv-1包膜靶向臂的双特异性分子
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
DK3221346T3
(da)
|
2014-11-21 |
2020-10-12 |
Bristol Myers Squibb Co |
Antistoffer omfattende modificerede konstante områder af tungkæden
|
HUE050596T2
(hu)
|
2014-11-21 |
2020-12-28 |
Bristol Myers Squibb Co |
Antitestek CD73 ellen és azok felhasználásai
|
GB201421901D0
(en)
|
2014-12-09 |
2015-01-21 |
Cambridge Entpr Ltd |
A method of rational antibody design
|
ES2834739T3
(es)
|
2014-12-11 |
2021-06-18 |
Pf Medicament |
Anticuerpos anti-C10orf54 y utilizaciones de los mismos
|
US20160168237A1
(en)
|
2014-12-12 |
2016-06-16 |
Alexion Pharmaceuticals, Inc. |
Method for treating a complement mediated disorder caused by an infectious agent in a patient
|
CA2963760A1
(en)
|
2014-12-19 |
2016-06-23 |
Yoshinao Ruike |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
EP3237450B1
(en)
|
2014-12-22 |
2021-03-03 |
The Rockefeller University |
Anti-mertk agonistic antibodies and uses thereof
|
AU2015369683C1
(en)
|
2014-12-23 |
2024-06-20 |
Bristol-Myers Squibb Company |
Antibodies to TIGIT
|
PE20171154A1
(es)
|
2014-12-30 |
2017-08-16 |
Hanmi Pharm Ind Co Ltd |
Derivados de glucagon con estabilidad mejorada
|
KR102418477B1
(ko)
|
2014-12-30 |
2022-07-08 |
한미약품 주식회사 |
글루카곤 유도체
|
GB2557389B
(en)
|
2015-01-14 |
2020-12-23 |
Brigham & Womens Hospital Inc |
Treatment of cancer with anti-lap monoclonal antibodies
|
WO2016123454A1
(en)
|
2015-01-29 |
2016-08-04 |
Board Of Trustees Of Miching State University |
Cryptic polypeptides and uses thereof
|
EA201791754A1
(ru)
|
2015-02-05 |
2019-01-31 |
Чугаи Сейяку Кабусики Кайся |
АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
|
EP3260139A4
(en)
|
2015-02-17 |
2018-09-05 |
Hanmi Pharm. Co., Ltd. |
Long-acting insulin or insulin analogue complex
|
EP3265491A1
(en)
|
2015-03-03 |
2018-01-10 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
PL3265123T3
(pl)
|
2015-03-03 |
2023-03-13 |
Kymab Limited |
Przeciwciała, zastosowania i sposoby
|
MX2017012102A
(es)
|
2015-03-20 |
2018-01-12 |
Pfizer |
Agentes citotoxicos bifuncionales que contienen el farmacoforo de cti.
|
HRP20230060T1
(hr)
|
2015-05-29 |
2023-03-17 |
Bristol-Myers Squibb Company |
Antitijela protiv ox40 i njihova primjena
|
JP2018522540A
(ja)
|
2015-06-05 |
2018-08-16 |
ノバルティス アーゲー |
骨形成タンパク質9(bmp9)を標的とする抗体およびそれらのための方法
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
BR112017028353A2
(pt)
|
2015-06-29 |
2018-09-04 |
The Rockfeller University |
anticorpos para cd40 com atividade agonista melhorada
|
MX2017016845A
(es)
|
2015-06-30 |
2018-08-01 |
Hanmi Pharm Ind Co Ltd |
Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo.
|
RU2752530C2
(ru)
|
2015-08-03 |
2021-07-29 |
Новартис Аг |
Способы лечения расстройств, связанных с fgf21
|
CN108289928A
(zh)
|
2015-08-06 |
2018-07-17 |
哈佛大学校长及研究员协会 |
改进的微生物-结合分子和其用途
|
UY36870A
(es)
|
2015-08-28 |
2017-03-31 |
Hanmi Pharm Ind Co Ltd |
Análogos de insulina novedosos
|
MX2018002315A
(es)
|
2015-09-01 |
2018-04-11 |
Agenus Inc |
Anticuerpos anti muerte programada 1 (pd 1) y metodos de uso de los mismos.
|
US10000561B2
(en)
|
2015-09-09 |
2018-06-19 |
Novartis Ag |
Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
|
KR20180042433A
(ko)
|
2015-09-09 |
2018-04-25 |
노파르티스 아게 |
흉선 기질 림포포이에틴 (tslp)-결합 항체 및 항체의 사용 방법
|
AU2016323440B2
(en)
|
2015-09-15 |
2023-07-13 |
Amgen Inc. |
Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
|
JP7222710B2
(ja)
|
2015-09-24 |
2023-02-15 |
ハンミ ファーマシューティカル カンパニー リミテッド |
免疫グロブリン断片の特定位置を連結部位として用いたタンパク質結合体
|
AR106184A1
(es)
|
2015-09-29 |
2017-12-20 |
Celgene Corp |
Proteínas de unión a pd-1 y sus métodos de uso
|
WO2017058944A1
(en)
|
2015-09-29 |
2017-04-06 |
Amgen Inc. |
Asgr inhibitors
|
MX2018004041A
(es)
|
2015-10-01 |
2018-11-09 |
Amgen Inc |
Tratamiento de trastornos de acidos biliares.
|
EP3370771A4
(en)
|
2015-11-03 |
2019-06-19 |
Ambrx, Inc. |
ANTI-CD3-FOLATE CONJUGATES AND USES THEREOF
|
JP6486316B2
(ja)
|
2015-11-03 |
2019-03-20 |
財團法人工業技術研究院Industrial Technology Research Institute |
抗体−薬物複合体(adc)およびそれを形成するための方法
|
MX2018006072A
(es)
|
2015-11-19 |
2018-08-01 |
Squibb Bristol Myers Co |
Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
|
EP3383910A1
(en)
|
2015-11-30 |
2018-10-10 |
AbbVie Inc. |
ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
|
US10188660B2
(en)
|
2015-11-30 |
2019-01-29 |
Abbvie Inc. |
Anti-huLRRC15 antibody drug conjugates and methods for their use
|
US11447557B2
(en)
|
2015-12-02 |
2022-09-20 |
Agenus Inc. |
Antibodies and methods of use thereof
|
US10144768B2
(en)
|
2015-12-04 |
2018-12-04 |
Novartis Ag |
Antibody cytokine engrafted compositions and methods of use for immunoregulation
|
MX2018006218A
(es)
|
2015-12-04 |
2018-09-05 |
Seattle Genetics Inc |
Conjugados de compuestos de tubulisina cuaternizada.
|
US20170157215A1
(en)
|
2015-12-04 |
2017-06-08 |
Jomoco, Corp. |
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
|
US10822408B2
(en)
|
2015-12-15 |
2020-11-03 |
Amgen Inc. |
PACAP antibodies and uses thereof
|
CR20180365A
(es)
|
2015-12-16 |
2018-09-28 |
Amgen Inc |
PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
|
JP2019506844A
(ja)
|
2015-12-18 |
2019-03-14 |
ノバルティス アーゲー |
CD32bを標的とする抗体およびその使用方法
|
EP3394098A4
(en)
|
2015-12-25 |
2019-11-13 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
|
CN108699125B
(zh)
|
2015-12-31 |
2022-10-28 |
韩美药品株式会社 |
胰高血糖素/glp-1/gip受体三重激动剂
|
CN108473569B
(zh)
|
2016-01-11 |
2022-11-22 |
苏黎世大学 |
针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白
|
EP3851457A1
(en)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
AR107483A1
(es)
|
2016-01-29 |
2018-05-02 |
Hanmi Pharm Ind Co Ltd |
Conjugado de enzimas terapéuticas
|
WO2017134547A1
(en)
|
2016-02-01 |
2017-08-10 |
Pfizer Inc. |
Tubulysin analogs and methods for their preparation
|
US20190284293A1
(en)
|
2016-03-04 |
2019-09-19 |
Bristol-Myers Squibb Company |
Combination therapy with anti-cd73 antibodies
|
EP3423489A1
(en)
|
2016-03-04 |
2019-01-09 |
The Rockefeller University |
Antibodies to cd40 with enhanced agonist activity
|
AR107823A1
(es)
|
2016-03-07 |
2018-06-06 |
Hanmi Pharm Ind Co Ltd |
Derivados de polietilenglicol y uso de los mismos
|
KR20180127407A
(ko)
|
2016-03-16 |
2018-11-28 |
메리맥 파마슈티컬즈, 인크. |
암 요법용 조작된 trail
|
KR20220004226A
(ko)
|
2016-03-22 |
2022-01-11 |
바이오노믹스 리미티드 |
항-lgr5 단클론성 항체의 투여
|
UA125510C2
(uk)
|
2016-03-25 |
2022-04-13 |
Сіджен Інк. |
Спосіб отримання пегильованої сполуки лікарський препарат-лінкер, де лікарським препаратом є ауристатин, та її проміжних сполук
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
KR102673420B1
(ko)
|
2016-04-04 |
2024-06-07 |
바이오버라티브 유에스에이 인코포레이티드 |
항-보체 인자 bb 항체 및 이의 용도
|
PE20190353A1
(es)
|
2016-04-15 |
2019-03-07 |
Macrogenics Inc |
Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos
|
AU2017254674A1
(en)
|
2016-04-21 |
2018-11-01 |
Abbvie Stemcentrx Llc |
Novel anti-BMPR1B antibodies and methods of use
|
JP7138567B2
(ja)
|
2016-04-27 |
2022-09-16 |
ノバルティス アーゲー |
成長分化因子15に対する抗体およびそれらの使用
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
KR102463844B1
(ko)
*
|
2016-05-27 |
2022-11-08 |
알토 바이오사이언스 코포레이션 |
Cd3 결합 도메인을 가지는 다량체 il-15 기반 분자의 구성 및 특성규명
|
JP7267012B2
(ja)
|
2016-05-27 |
2023-05-01 |
アジェナス インコーポレイテッド |
抗tim-3抗体及びその使用方法
|
EP4371570A3
(en)
|
2016-06-08 |
2024-07-17 |
Xencor, Inc. |
Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
|
KR102492057B1
(ko)
|
2016-06-15 |
2023-01-26 |
노파르티스 아게 |
골 형태형성 단백질 6(bmp6)의 억제제를 사용한 질병의 치료 방법
|
EP3471762A4
(en)
|
2016-06-16 |
2020-03-11 |
The Board of Trustees of the Leland Stanford Junior University |
HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODIES DIRECTED AGAINST CD81
|
IL299221A
(en)
|
2016-06-21 |
2023-02-01 |
Teneobio Inc |
CD3 binding antibodies
|
UA126662C2
(uk)
|
2016-06-29 |
2023-01-11 |
Ханмі Фарм. Ко., Лтд. |
Похідна глюкагону, її кон'югат, композиція, яка її містить, та її терапевтичне застосування
|
JP2019525772A
(ja)
|
2016-07-08 |
2019-09-12 |
スターテン・バイオテクノロジー・ベー・フェー |
抗apoc3抗体およびその使用方法
|
TWI780057B
(zh)
|
2016-07-14 |
2022-10-11 |
美商必治妥美雅史谷比公司 |
針對tim3之抗體及其用途
|
AU2017325654A1
(en)
|
2016-08-02 |
2019-02-14 |
Visterra, Inc. |
Engineered polypeptides and uses thereof
|
EP3493853A1
(en)
|
2016-08-03 |
2019-06-12 |
Pfizer Inc |
Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
|
CA3026050A1
(en)
|
2016-08-05 |
2018-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Composition for prophylaxis or treatment of il-8 related diseases
|
EA201990470A1
(ru)
|
2016-08-09 |
2019-09-30 |
Сиэтл Дженетикс, Инк. |
Конъюгаты лекарственного средства с самостабилизирующимися линкерами, имеющие улучшенные физико-химические свойства
|
WO2018044970A1
(en)
|
2016-08-31 |
2018-03-08 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
|
JP7030109B2
(ja)
|
2016-09-14 |
2022-03-04 |
テネオバイオ, インコーポレイテッド |
Cd3結合抗体
|
WO2018053401A1
(en)
|
2016-09-19 |
2018-03-22 |
Celgene Corporation |
Methods of treating vitiligo using pd-1 binding proteins
|
KR102257154B1
(ko)
|
2016-09-19 |
2021-05-28 |
셀진 코포레이션 |
Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법
|
KR20180033105A
(ko)
|
2016-09-23 |
2018-04-02 |
한미약품 주식회사 |
인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도
|
MX2019003683A
(es)
|
2016-10-11 |
2019-08-22 |
Agenus Inc |
Anticuerpos anti gen 3 de activación linfocítica (lag 3 ) y métodos para usarlos.
|
US11638762B2
(en)
|
2016-10-18 |
2023-05-02 |
Seagen Inc. |
Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
|
JP7096240B2
(ja)
|
2016-10-19 |
2022-07-05 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
試料中の非結合c5の定量化方法
|
CA3200275A1
(en)
|
2016-10-21 |
2018-04-26 |
Nantcell, Inc. |
Multimeric il-15-based molecules
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
CA3041340A1
(en)
|
2016-11-09 |
2018-05-17 |
Agenus Inc. |
Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
|
US20230137351A1
(en)
|
2016-11-14 |
2023-05-04 |
Amgen Inc. |
Bispecific or biparatopic antigen binding proteins and uses thereof
|
CR20190297A
(es)
|
2016-11-23 |
2019-11-01 |
Bioverativ Therapeutics Inc |
Anticuerpos biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x
|
JP2019536823A
(ja)
|
2016-12-05 |
2019-12-19 |
ハンミ ファーマシューティカル カンパニー リミテッド |
免疫反応が弱化された結合体
|
WO2018104893A1
(en)
|
2016-12-06 |
2018-06-14 |
Glaxosmithkline Intellectual Property Development Limited |
Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
|
JP7106538B2
(ja)
|
2016-12-07 |
2022-07-26 |
アジェナス インコーポレイテッド |
抗体およびその使用方法
|
MD3551660T2
(ro)
|
2016-12-07 |
2024-03-31 |
Agenus Inc |
Anticorpi anti-CTLA-4 și procedee de utilizare a acestora
|
US20190352335A1
(en)
|
2016-12-19 |
2019-11-21 |
Hanmi Pharm. Co., Ltd. |
Brain targeting long-acting protein conjugate
|
WO2018116267A2
(en)
|
2016-12-23 |
2018-06-28 |
Novartis Ag |
Methods of treatment with anti-factor xi/xia antibodies
|
IL308980A
(en)
|
2016-12-23 |
2024-01-01 |
Novartis Ag |
Antibodies against factor XI and methods of their use
|
CA3049424A1
(en)
|
2017-01-06 |
2018-07-12 |
Avidity Biosciences Llc |
Nucleic acid-polypeptide compositions and methods of inducing exon skipping
|
WO2018129451A2
(en)
|
2017-01-09 |
2018-07-12 |
Merrimack Pharmaceuticals, Inc. |
Anti-fgfr antibodies and methods of use
|
AU2018211561B2
(en)
|
2017-01-24 |
2020-04-30 |
Pfizer Inc. |
Calicheamicin derivatives and antibody drug conjugates thereof
|
WO2018143729A1
(ko)
|
2017-02-03 |
2018-08-09 |
한미약품 주식회사 |
지속성이 증가된 생리활성 물질의 결합체 및 이의 용도
|
CN110545852B
(zh)
|
2017-02-07 |
2023-05-26 |
韩美药品株式会社 |
非肽聚合物接头化合物、包含该接头化合物的缀合物及制备该接头化合物和缀合物的方法
|
US10899844B2
(en)
|
2017-02-08 |
2021-01-26 |
Novartis Ag |
FGF21 mimetic antibodies and uses thereof
|
SG11201906947SA
(en)
|
2017-02-17 |
2019-08-27 |
Bristol Myers Squibb Co |
Antibodies to alpha-synuclein and uses thereof
|
US11129883B2
(en)
|
2017-03-06 |
2021-09-28 |
Altor BioScience, LLC. |
IL-15-based fusions to IL-12 and IL-18
|
KR101941975B1
(ko)
|
2017-03-17 |
2019-01-25 |
고려대학교 산학협력단 |
Atpif1을 함유하는 당뇨 치료용 약학조성물
|
AU2018239037B2
(en)
|
2017-03-23 |
2022-05-26 |
Hanmi Pharm. Co., Ltd. |
Insulin analog complex with reduced affinity for insulin receptor and use thereof
|
US11730822B2
(en)
|
2017-03-24 |
2023-08-22 |
Seagen Inc. |
Process for the preparation of glucuronide drug-linkers and intermediates thereof
|
US20190048055A1
(en)
|
2017-03-31 |
2019-02-14 |
Altor Bioscience Corporation |
Alt-803 in combination with anti-cd38 antibody for cancer therapies
|
CN110505885A
(zh)
|
2017-04-05 |
2019-11-26 |
诺和诺德股份有限公司 |
寡聚体延伸的胰岛素-Fc缀合物
|
CN110709417B
(zh)
|
2017-04-07 |
2023-10-31 |
美天施生物科技有限责任两合公司 |
具有突变人IgG4的多肽
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
AU2018253176B2
(en)
|
2017-04-13 |
2023-02-02 |
Agenus Inc. |
Anti-CD137 antibodies and methods of use thereof
|
JOP20190248A1
(ar)
|
2017-04-21 |
2019-10-20 |
Amgen Inc |
بروتينات ربط مولد ضد trem2 واستخداماته
|
AU2018255938A1
(en)
|
2017-04-21 |
2019-10-31 |
Staten Biotechnology B.V. |
Anti-ApoC3 antibodies and methods of use thereof
|
US11643473B2
(en)
|
2017-04-24 |
2023-05-09 |
Alexion Pharmaceuticals, Inc. |
Antibody immune cell inhibitor fusion proteins
|
WO2018201087A1
(en)
|
2017-04-27 |
2018-11-01 |
Seattle Genetics, Inc. |
Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
|
SI3618863T1
(sl)
|
2017-05-01 |
2023-12-29 |
Agenus Inc. |
Protitelesa proti tigitu in načini uporabe njih
|
CN111094335B
(zh)
|
2017-05-15 |
2022-08-23 |
罗切斯特大学 |
广泛中和的抗流感单克隆抗体及其用途
|
EP3630162A1
(en)
|
2017-05-24 |
2020-04-08 |
Novartis AG |
Antibody-cytokine engrafted proteins and methods of use
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
EP3630813A1
(en)
|
2017-05-24 |
2020-04-08 |
Novartis AG |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
JOP20190271A1
(ar)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
CN116333129A
(zh)
|
2017-05-25 |
2023-06-27 |
百时美施贵宝公司 |
包含经修饰的重链恒定区的抗体
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
EP3642237A2
(en)
|
2017-06-20 |
2020-04-29 |
Teneobio, Inc. |
Anti-bcma heavy chain-only antibodies
|
AU2018288803A1
(en)
|
2017-06-20 |
2020-02-06 |
Teneoone, Inc. |
Anti-BCMA heavy chain-only antibodies
|
CN111094559A
(zh)
|
2017-07-07 |
2020-05-01 |
韩美药品株式会社 |
新型治疗酶融合蛋白及其用途
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
DK3658184T3
(da)
|
2017-07-27 |
2023-11-27 |
Alexion Pharma Inc |
Højkoncentrerede anti-c5-antistofformuleringer
|
CN111094352A
(zh)
|
2017-08-25 |
2020-05-01 |
戊瑞治疗有限公司 |
B7-h4抗体及其使用方法
|
KR20200090742A
(ko)
|
2017-08-28 |
2020-07-29 |
알토 바이오사이언스 엘엘씨 |
Il-7 및 il-21에의 il-15 기반 융합
|
SG11202002093TA
(en)
|
2017-09-13 |
2020-04-29 |
Teneobio Inc |
Heavy chain antibodies binding to ectoenzymes
|
BR112020006189A2
(pt)
|
2017-09-28 |
2020-10-13 |
Hanmi Pharm. Co., Ltd. |
conjugado de peptídeo-2 tipo glucagon (glp-2), derivado de glp-2 que compreende uma sequência de aminoácidos e seu método se preparação, ácido nucleico isolado que codifica o derivado de glp-2, vetor de expressão recombinante que compreende o ácido nucleico, transformante que compreende o vetor de expressão recombinante, composição farmacêutica para prevenir ou tratar uma ou mais doenças selecionadas
|
KR20190036956A
(ko)
|
2017-09-28 |
2019-04-05 |
한미약품 주식회사 |
지속형 단쇄 인슐린 아날로그 및 이의 결합체
|
JP7377195B2
(ja)
|
2017-09-29 |
2023-11-09 |
ハンミ ファーマシューティカル カンパニー リミテッド |
リンカーとして非ペプチド性重合体結合脂肪酸誘導体化合物を含むタンパク質結合体及びその製造方法
|
WO2019066603A1
(ko)
|
2017-09-29 |
2019-04-04 |
한미약품 주식회사 |
효력이 향상된 지속성 단백질 결합체
|
CN111655268B
(zh)
|
2017-10-04 |
2024-03-26 |
艾维迪提生物科学公司 |
核酸-多肽组合物及其用途
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
WO2019073069A1
(en)
|
2017-10-13 |
2019-04-18 |
Boehringer Ingelheim International Gmbh |
HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
US10538583B2
(en)
|
2017-10-31 |
2020-01-21 |
Staten Biotechnology B.V. |
Anti-APOC3 antibodies and compositions thereof
|
PE20210119A1
(es)
|
2017-10-31 |
2021-01-19 |
Staten Biotechnology B V |
Anticuerpos anti-apoc3 y metodos de uso de estos
|
KR20240007965A
(ko)
|
2017-12-06 |
2024-01-17 |
어비디티 바이오사이언시스 인크. |
근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법
|
CN111601613A
(zh)
|
2017-12-22 |
2020-08-28 |
诺华股份有限公司 |
用fgf21变体治疗代谢障碍的方法
|
EA202091239A1
(ru)
|
2017-12-22 |
2020-09-09 |
Ханми Фарм. Ко., Лтд. |
Слитый белок на основе терапевтического фермента, имеющий новую структуру, и его применение
|
KR20200104342A
(ko)
|
2017-12-22 |
2020-09-03 |
테네오바이오, 인코포레이티드 |
Cd22에 결합하는 중쇄 항체
|
JP7284759B2
(ja)
|
2017-12-27 |
2023-05-31 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗cd40抗体およびその使用
|
JP2021508479A
(ja)
*
|
2017-12-27 |
2021-03-11 |
テネオバイオ, インコーポレイテッド |
ヘテロ二量体特異的抗体上のcd3デルタ及びcd3イプシロン
|
WO2019129054A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
三链抗体、其制备方法及其用途
|
JP7339262B2
(ja)
|
2018-01-12 |
2023-09-05 |
アムジェン インコーポレイテッド |
Pac1抗体及びその使用
|
KR20200108870A
(ko)
|
2018-01-12 |
2020-09-21 |
브리스톨-마이어스 스큅 컴퍼니 |
Tim3에 대한 항체 및 그의 용도
|
EP3755707A1
(en)
|
2018-02-20 |
2020-12-30 |
Seagen Inc. |
Hydrophobic auristatin f compounds and conjugates thereof
|
CA3091144A1
(en)
*
|
2018-03-01 |
2019-09-06 |
Igm Biosciences, Inc. |
Igm fc and j-chain mutations that affect igm serum half-life
|
WO2019169212A1
(en)
|
2018-03-02 |
2019-09-06 |
Five Prime Therapeutics, Inc. |
B7-h4 antibodies and methods of use thereof
|
MX2020009861A
(es)
|
2018-03-23 |
2020-10-08 |
Bristol Myers Squibb Co |
Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos.
|
TW202003011A
(zh)
|
2018-03-26 |
2020-01-16 |
美商艾爾特生物科技責任有限公司 |
抗PDL1、IL-15及TGF-β受體組合分子
|
CN110305210B
(zh)
|
2018-03-27 |
2023-02-28 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
WO2019184909A1
(zh)
|
2018-03-27 |
2019-10-03 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
US20210046189A1
(en)
|
2018-03-30 |
2021-02-18 |
HANMl PHARM. CO., LTD. |
Long-acting protein conjugates for brain targeting, a preparation method thereof, and a composition comprising the same
|
MA52190A
(fr)
|
2018-04-02 |
2021-02-17 |
Bristol Myers Squibb Co |
Anticorps anti-trem-1 et utilisations associées
|
US11820801B2
(en)
|
2018-04-26 |
2023-11-21 |
Good T Cells, Inc. |
Fusion protein, and pharmaceutical composition for preventing or treating cancer, containing same
|
CA3096703A1
(en)
|
2018-05-03 |
2019-11-07 |
University Of Rochester |
Anti-influenza neuraminidase monoclonal antibodies and uses thereof
|
AU2019265699A1
(en)
|
2018-05-08 |
2021-01-07 |
Amgen Inc. |
Bispecific antibodies with cleavable C-terminal charge-paired tags
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
JP7398396B2
(ja)
|
2018-06-01 |
2023-12-14 |
ノバルティス アーゲー |
Bcmaに対する結合分子及びその使用
|
TW202015740A
(zh)
|
2018-06-07 |
2020-05-01 |
美商西雅圖遺傳學公司 |
喜樹鹼結合物
|
TW202016151A
(zh)
|
2018-06-09 |
2020-05-01 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
BR112020025111A2
(pt)
|
2018-06-15 |
2021-04-06 |
Proclara Biosciences, Inc. |
Motivo de interação amiloide geral (gaim)
|
KR20210032311A
(ko)
|
2018-07-20 |
2021-03-24 |
테네오바이오, 인코포레이티드 |
Cd19에 결합하는 중쇄 항체
|
MX2021000786A
(es)
|
2018-07-20 |
2021-06-15 |
Pf Medicament |
Receptor para supresor de ig del dominio v de activación de células t (vista).
|
US20210347849A1
(en)
|
2018-07-24 |
2021-11-11 |
Good T Cells, Inc. |
Composition for Preventing or Treating Immune-Related Diseases
|
CA3113057A1
(en)
|
2018-09-21 |
2020-03-26 |
Teneobio, Inc. |
Methods for purifying heterodimeric, multispecific antibodies
|
CN110964116A
(zh)
|
2018-09-26 |
2020-04-07 |
北京辅仁瑞辉生物医药研究院有限公司 |
GLP1-Fc融合蛋白及其缀合物
|
CA3113575A1
(en)
|
2018-10-03 |
2020-04-09 |
Staten Biotechnology B.V. |
Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
|
US20210338779A1
(en)
|
2018-10-04 |
2021-11-04 |
Hanmi Pharm. Co., Ltd |
Therapeutic use of glucagon and combination including the same
|
CN112839681A
(zh)
|
2018-10-10 |
2021-05-25 |
诺和诺德股份有限公司 |
寡聚体延伸的胰岛素-Fc缀合物及其医学用途
|
EP3863722A2
(en)
|
2018-10-10 |
2021-08-18 |
Tilos Theapeutics, Inc. |
Anti-lap antibody variants and uses thereof
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
TWI824043B
(zh)
|
2018-10-25 |
2023-12-01 |
西班牙商瑪製藥股份有限公司 |
藥物抗體共軛物
|
US20210388106A1
(en)
|
2018-10-26 |
2021-12-16 |
Teneobio, Inc. |
Heavy chain antibodies binding to cd38
|
WO2020102501A1
(en)
|
2018-11-16 |
2020-05-22 |
Bristol-Myers Squibb Company |
Anti-nkg2a antibodies and uses thereof
|
CN113348177A
(zh)
|
2018-11-28 |
2021-09-03 |
百时美施贵宝公司 |
包含经修饰的重链恒定区的抗体
|
KR102630499B1
(ko)
|
2018-12-21 |
2024-01-30 |
어비디티 바이오사이언시스 인크. |
항트랜스페린 수용체 항체 및 이의 용도
|
EP3900735A4
(en)
|
2018-12-21 |
2022-09-07 |
Hanmi Pharm. Co., Ltd. |
PHARMACEUTICAL COMPOSITION WITH INSULIN AND TRIPLE AGONOISTS WITH ACTIVITY AGAINST ALL GLUCAGON AND GLP-1 AND GIP RECEPTORS
|
KR20200078414A
(ko)
|
2018-12-21 |
2020-07-01 |
한미약품 주식회사 |
인슐린 및 글루카곤을 포함하는 약학 조성물
|
PE20212305A1
(es)
|
2019-01-22 |
2021-12-10 |
Bristol Myers Squibb Co |
Anticuerpos contra subunidad alfa il-7r y usos de estos
|
MA55080A
(fr)
|
2019-02-26 |
2022-01-05 |
Inspirna Inc |
Anticorps anti-mertk à affinité élevée et utilisations associées
|
AU2020252556A1
(en)
|
2019-04-05 |
2021-10-21 |
Teneobio, Inc. |
Heavy chain antibodies binding to PSMA
|
KR102524577B1
(ko)
|
2019-04-22 |
2023-04-21 |
전남대학교산학협력단 |
플라젤린 융합 단백질 및 이의 용도
|
US20220409734A1
(en)
|
2019-05-10 |
2022-12-29 |
Yutaka Nishimoto |
Antibody drug conjugates
|
AU2020279974A1
(en)
|
2019-05-21 |
2021-11-18 |
Novartis Ag |
CD19 binding molecules and uses thereof
|
WO2020236797A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
MA56033A
(fr)
|
2019-05-24 |
2022-04-06 |
Sanofi Sa |
Méthodes de traitement de la sclérodermie généralisée
|
WO2020243477A2
(en)
|
2019-05-30 |
2020-12-03 |
Amgen Inc. |
Engineering the hinge region to drive antibody dimerization
|
CN114375297A
(zh)
|
2019-06-06 |
2022-04-19 |
艾维迪提生物科学公司 |
Una亚酰胺及其用途
|
JP2022535588A
(ja)
|
2019-06-06 |
2022-08-09 |
アビディティー バイオサイエンシーズ,インク. |
核酸ポリペプチド組成物およびその使用
|
WO2020245420A1
(en)
|
2019-06-07 |
2020-12-10 |
Argenx Bvba |
PHARMACEUTICAL FORMULATIONS OF FcRn INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINISTRATION
|
CA3140816A1
(en)
|
2019-06-14 |
2020-12-17 |
Nathan Trinklein |
Multispecific heavy chain antibodies binding to cd22 and cd3
|
CA3143524A1
(en)
|
2019-06-28 |
2020-12-30 |
Amgen Inc. |
Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
|
PL3936142T3
(pl)
|
2019-06-28 |
2024-05-06 |
Hanmi Pharm. Co., Ltd. |
Potrójny agonista wykazujący aktywność względem wszystkich pośród receptorów glukagonu, glp-1 oraz gip do leczenia chorób wątroby
|
CN114174536A
(zh)
|
2019-07-15 |
2022-03-11 |
百时美施贵宝公司 |
抗trem-1抗体及其用途
|
CN114144435B
(zh)
|
2019-07-15 |
2024-06-25 |
百时美施贵宝公司 |
针对人trem-1的抗体及其用途
|
US11717577B2
(en)
|
2019-07-18 |
2023-08-08 |
Hanmi Pharm. Co., Ltd. |
Method for preparing long-acting drug conjugate through preparation of intermediate
|
EP4004050A2
(en)
|
2019-07-30 |
2022-06-01 |
QLSF Biotherapeutics Inc. |
Multispecific binding compound that bind to lfrrc15 and cd3
|
MX2022001882A
(es)
|
2019-08-12 |
2022-05-30 |
Aptevo Res & Development Llc |
Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
|
TW202122420A
(zh)
|
2019-08-30 |
2021-06-16 |
美商艾吉納斯公司 |
抗cd96抗體及其使用方法
|
EP4025253B1
(en)
|
2019-09-05 |
2024-03-20 |
Pharma Mar, S.A. |
Drug antibody conjugates
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
US20210138077A1
(en)
|
2019-09-19 |
2021-05-13 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|
WO2021067820A1
(en)
|
2019-10-04 |
2021-04-08 |
Seagen Inc. |
Formulation of antibody-drug conjugate
|
JP2022550851A
(ja)
|
2019-10-04 |
2022-12-05 |
シージェン インコーポレイテッド |
カンプトテシンペプチドコンジュゲート
|
JP2022551282A
(ja)
|
2019-10-04 |
2022-12-08 |
ハンミ ファーマシューティカル カンパニー リミテッド |
グルカゴン、及びglp-1受容体及びgip受容体二重アゴニストを含む組成物及びその治療学的使用
|
US20220380487A1
(en)
|
2019-10-24 |
2022-12-01 |
Minotaur Therapeutics, Inc. |
Chimeric cytokine modified antibodies and methods of use thereof
|
CA3160482A1
(en)
|
2019-11-08 |
2021-05-14 |
Amgen Inc. |
Engineering charge pair mutations for pairing of hetero-igg molecules
|
AU2020386005A1
(en)
|
2019-11-19 |
2022-05-26 |
Amgen Inc. |
Novel multispecific antibody format
|
KR20220114559A
(ko)
|
2019-12-18 |
2022-08-17 |
테네오포, 인코포레이티드 |
Cd38에 결합하는 중쇄 항체
|
CA3164129A1
(en)
|
2019-12-20 |
2021-06-24 |
Amgen Inc. |
Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors
|
GB201919061D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibody
|
KR20210082120A
(ko)
|
2019-12-24 |
2021-07-02 |
한미약품 주식회사 |
Glp-2 또는 이의 결합체를 포함하는 골 대사성 질환에 대한 예방 또는 치료용 약학적 조성물
|
EP4104849A4
(en)
|
2020-01-13 |
2024-03-27 |
Hanmi Pharm. Co., Ltd. |
THERAPEUTIC USE OF A LONG-ACTING CONJUGATE OF A TRIPLE AGONIST WITH ACTIVITY RELATED TO GLUCAGON AND GLP-1 AND GIP RECEPTORS AGAINST LUNG DISEASE
|
AU2021226341A1
(en)
|
2020-02-25 |
2022-09-29 |
Mediboston Limited |
Camptothecin derivatives and conjugates thereof
|
EP4121063A4
(en)
|
2020-03-19 |
2024-07-03 |
Avidity Biosciences Inc |
COMPOSITIONS AND METHODS FOR TREATING FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY
|
US11365239B2
(en)
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
WO2021195574A1
(en)
*
|
2020-03-27 |
2021-09-30 |
Alnylam Pharmaceuticals, Inc. |
Fc FRAGMENT OF IgG RECEPTOR AND TRANSPORTER (FCGRT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
KR20220161378A
(ko)
|
2020-03-27 |
2022-12-06 |
어비디티 바이오사이언시스 인크. |
근이영양증의 치료용 조성물 및 방법
|
KR20210121585A
(ko)
|
2020-03-30 |
2021-10-08 |
한국세라믹기술원 |
반응성 및 안정성 그리고 항체회수가 향상된 z-도메인 및 칼시퀘스트린 융합단백질 및 이를 이용한 항체의 분리 및 정제 방법
|
JP2023519930A
(ja)
|
2020-04-01 |
2023-05-15 |
ユニバーシティ オブ ロチェスター |
インフルエンザh3n2ウイルスのヘマグルチニン(ha)およびノイラミニダーゼ(na)に対するモノクローナル抗体
|
US20230159607A1
(en)
|
2020-04-03 |
2023-05-25 |
Hanmi Pharm. Co., Ltd. |
Pharmaceutical composition for preventing or treating mucositis induced by radiotherapy, chemotherapy, or combination thereof, comprising glp-2 derivatives or long-acting conjugate of same
|
WO2021207449A1
(en)
|
2020-04-09 |
2021-10-14 |
Merck Sharp & Dohme Corp. |
Affinity matured anti-lap antibodies and uses thereof
|
JP2023522102A
(ja)
|
2020-04-20 |
2023-05-26 |
ジェンザイム・コーポレーション |
ヒト化抗補体Bb因子抗体およびその使用
|
JP2023521491A
(ja)
|
2020-04-20 |
2023-05-24 |
ハンミ ファーマシューティカル カンパニー リミテッド |
グルカゴン、glp-1及びgip受容体の全てに対して活性を有する三重活性体又はその結合体を含む高脂血症の予防又は治療用薬学的組成物及び予防又は治療方法
|
WO2021214126A1
(en)
|
2020-04-21 |
2021-10-28 |
Pharma Mar, S.A. |
Drug antibody conjugates
|
US11634477B2
(en)
|
2020-04-28 |
2023-04-25 |
The Rockefeller University |
Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof
|
UY39191A
(es)
|
2020-04-29 |
2021-11-30 |
Teneobio Inc |
Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
|
AU2021263926A1
(en)
|
2020-04-29 |
2023-01-19 |
Teneoone, Inc. |
Methods of treating multiple myeloma
|
CN115894703A
(zh)
|
2020-04-29 |
2023-04-04 |
特尼奥生物股份有限公司 |
具有经修饰重链恒定区的多特异性重链抗体
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
JP2023528235A
(ja)
|
2020-05-17 |
2023-07-04 |
アストラゼネカ・ユーケイ・リミテッド |
SARS-CoV-2抗体、並びにこれを選択及び使用する方法
|
WO2021235913A1
(ko)
|
2020-05-22 |
2021-11-25 |
한미약품 주식회사 |
Glp-2의 지속형 결합체의 액상 제제
|
BR112022023738A2
(pt)
|
2020-05-22 |
2023-01-31 |
Hanmi Pharm Ind Co Ltd |
Formulação líquida
|
JP2023526551A
(ja)
|
2020-05-22 |
2023-06-21 |
ハンミ ファーマシューティカル カンパニー リミテッド |
グルカゴン誘導体の持続型結合体の液状製剤
|
WO2021235916A1
(ko)
|
2020-05-22 |
2021-11-25 |
한미약품 주식회사 |
글루카곤, glp-1 및 gip 삼중 활성체의 지속형 결합체의 액상 제제
|
CN116209459A
(zh)
|
2020-06-26 |
2023-06-02 |
美国安进公司 |
Il-10突变蛋白及其融合蛋白
|
CN116472049A
(zh)
|
2020-06-30 |
2023-07-21 |
特尼奥生物股份有限公司 |
与bcma结合的多特异性抗体
|
KR20220009354A
(ko)
|
2020-07-15 |
2022-01-24 |
한미약품 주식회사 |
글루카곤 유도체 또는 이의 결합체의 간질환에 대한 치료적 용도
|
CA3186416A1
(en)
|
2020-07-17 |
2022-01-20 |
John A. Barrett |
Methods of treating chemotherapy induced neutropenia using fixed doses of g-csf protein complex
|
WO2022015115A1
(ko)
|
2020-07-17 |
2022-01-20 |
한미약품 주식회사 |
3중 작용성 지속형 결합체 또는 3중 작용제를 포함하는 조합물의 치료학적 용도
|
WO2022017309A1
(zh)
|
2020-07-24 |
2022-01-27 |
江苏晟斯生物制药有限公司 |
胰岛素-Fc融合蛋白及其应用
|
WO2022031978A1
(en)
|
2020-08-06 |
2022-02-10 |
Bioverativ Usa Inc. |
Inflammatory cytokines and fatigue in subject with a complement mediated disease
|
BR112023002234A2
(pt)
|
2020-08-10 |
2023-03-07 |
Astrazeneca Uk Ltd |
Anticorpos sars-cov-2 para tratamento e prevenção de covid-19
|
TW202220700A
(zh)
|
2020-08-14 |
2022-06-01 |
南韓商韓美藥品股份有限公司 |
包含三重升糖素/glp-1/gip受體促效劑的長效接合物的醫藥組成物
|
US20240024426A1
(en)
|
2020-08-14 |
2024-01-25 |
Hanmi Pharm. Co., Ltd. |
Hypotensive pharmaceutical composition comprising triple activator having activity for all of glucagon, glp-1, and gip receptors
|
JP2023538897A
(ja)
|
2020-08-20 |
2023-09-12 |
アムジエン・インコーポレーテツド |
Fab領域中に非標準的なジスルフィドを有する抗原結合タンパク質
|
WO2022065899A1
(ko)
|
2020-09-25 |
2022-03-31 |
한미약품 주식회사 |
글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체의 다발성 경화증의 치료 용도
|
CN116437967A
(zh)
|
2020-09-25 |
2023-07-14 |
韩美药品株式会社 |
包括对胰高血糖素、glp-1和glp受体全部具有活性的三重激动剂或其缀合物的用于预防或治疗骨病的药物组合物
|
JP2023543036A
(ja)
|
2020-09-25 |
2023-10-12 |
ハンミ ファーマシューティカル カンパニー リミテッド |
グルカゴン、glp-1及びgip受容体の全てに対して活性を有する三重活性体またはその結合体の神経退行性疾患の治療用途
|
JP2023544769A
(ja)
|
2020-10-07 |
2023-10-25 |
アムジエン・インコーポレーテツド |
多重特異性抗体の構築のためのビルディングブロックの合理的選択
|
WO2022080986A1
(ko)
|
2020-10-16 |
2022-04-21 |
한미약품 주식회사 |
Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물
|
KR20220050824A
(ko)
|
2020-10-16 |
2022-04-25 |
한미약품 주식회사 |
글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 호흡기 감염 질환의 후유증의 치료 용도
|
KR20220050821A
(ko)
|
2020-10-16 |
2022-04-25 |
한미약품 주식회사 |
글루카곤/glp-1/gip 삼중작용제 또는 이의 지속형 결합체를 포함하는 혈관염 예방 또는 치료용 약학적 조성물
|
US20240084014A1
(en)
|
2020-10-16 |
2024-03-14 |
Qlsf Biotherapeutics, Inc. |
Multispecific binding compounds that bind to pd-l1
|
JP2023546089A
(ja)
|
2020-10-16 |
2023-11-01 |
ハンミ ファーマシューティカルズ カンパニー リミテッド |
Gip誘導体またはその持続型結合体を含むループス関連疾患の予防用または治療用の薬学的組成物
|
US20230381331A1
(en)
|
2020-10-16 |
2023-11-30 |
Hanmi Pharm. Co., Ltd. |
Gip derivative, long-acting conjugate thereof, and pharmaceutical composition comprising same
|
WO2022080989A1
(ko)
|
2020-10-16 |
2022-04-21 |
한미약품 주식회사 |
글루카곤/glp-1/gip 삼중작용제 또는 이의 지속형 결합체를 포함하는 루푸스-관련 질환의 예방 또는 치료용 약학적 조성물
|
JP2023548878A
(ja)
|
2020-11-04 |
2023-11-21 |
ザ ロックフェラー ユニバーシティー |
中和抗sars-cov-2抗体
|
EP4240491A1
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Cd19 binding molecules and uses thereof
|
US20220168330A1
(en)
|
2020-11-09 |
2022-06-02 |
Takeda Pharmaceutical Company Limited |
Antibody drug conjugates
|
TW202233663A
(zh)
|
2020-11-10 |
2022-09-01 |
美商安進公司 |
多特異性抗原結合結構域之新穎的連接子
|
CN116419760A
(zh)
|
2020-11-13 |
2023-07-11 |
韩美药品株式会社 |
治疗酶融合蛋白在预防和治疗由法布里病引起或伴有法布里病的肾病中的用途
|
EP4245310A1
(en)
|
2020-11-13 |
2023-09-20 |
Hanmi Pharm. Co., Ltd. |
Use of therapeutic enzyme fusion protein in preventing and treating neuropathy attributed to or associated with farbry's disease
|
TW202233684A
(zh)
|
2020-11-18 |
2022-09-01 |
美商泰尼歐生物公司 |
結合於葉酸受體α之重鏈抗體
|
AU2021390501A1
(en)
|
2020-12-01 |
2023-06-29 |
Aptevo Research And Development Llc |
Heterodimeric psma and cd3-binding bispecific antibodies
|
IL303295A
(en)
|
2020-12-07 |
2023-07-01 |
UCB Biopharma SRL |
Multispecific antibodies and antibody combinations
|
WO2022131889A1
(ko)
|
2020-12-16 |
2022-06-23 |
주식회사 굳티셀 |
Taci 단백질의 용도
|
US20230382974A1
(en)
|
2020-12-24 |
2023-11-30 |
Hanmi Pharm. Co., Ltd. |
Novel triple agonist having activities on all of glucagon, glp-1, and gip receptors and use thereof
|
EP4302776A1
(en)
|
2020-12-24 |
2024-01-10 |
Hanmi Pharm. Co., Ltd. |
Combination therapy of insulinotropic peptide and glp-2, for preventing or treating short bowel syndrome
|
WO2022147463A2
(en)
|
2020-12-31 |
2022-07-07 |
Alamar Biosciences, Inc. |
Binder molecules with high affinity and/ or specificity and methods of making and use thereof
|
US20220227844A1
(en)
|
2021-01-15 |
2022-07-21 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
JP2024505943A
(ja)
|
2021-01-29 |
2024-02-08 |
ハンミ ファーマシューティカルズ カンパニー リミテッド |
Gip誘導体、またはその持続型結合体を含む肺疾患の予防用または治療用の薬学的組成物
|
AU2022226277A1
(en)
|
2021-02-25 |
2023-08-31 |
Teneobio, Inc. |
Anti-psma antibodies and car-t structures
|
US20240182597A1
(en)
|
2021-02-26 |
2024-06-06 |
Teneobio, Inc. |
Anti-muc1-c antibodies and car-t structures
|
IL305886A
(en)
|
2021-03-18 |
2023-11-01 |
Seagen Inc |
Selective release of drugs from internalized conjugates of biologically active compounds
|
MX2023010902A
(es)
|
2021-03-18 |
2023-09-27 |
Seagen Inc |
Liberacion selectiva de farmacos a partir de conjugados internalizados de compuestos biologicamente activos.
|
JP2024513837A
(ja)
|
2021-03-31 |
2024-03-27 |
バイオベラティブ・ユーエスエイ・インコーポレイテッド |
寒冷凝集素症患者における手術関連溶血の低減
|
MX2023010926A
(es)
|
2021-03-31 |
2023-09-27 |
Hanmi Pharmaceutical Co Ltd |
Novedoso conjugado de analogo de il-2 inmunoestimulante y procedimiento de preparacion del mismo.
|
TW202304994A
(zh)
|
2021-04-02 |
2023-02-01 |
美商泰尼歐生物公司 |
促效性抗il-2r抗體及使用方法
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型cdcp1に対する抗体およびその使用
|
JP2024514107A
(ja)
|
2021-04-06 |
2024-03-28 |
テネオバイオ, インコーポレイテッド |
抗cd19抗体及びcar-t構造体
|
US20240197834A1
(en)
|
2021-04-09 |
2024-06-20 |
Hanmi Pharm. Co., Ltd. |
Pharmaceutical composition for preventing or treating chronic renal disease including glucagon derivative
|
PE20240656A1
(es)
|
2021-04-16 |
2024-04-04 |
Teneobio Inc |
Anticuerpos anti-cd20 y estructuras car-t
|
JP2024515301A
(ja)
|
2021-04-20 |
2024-04-08 |
アムジエン・インコーポレーテツド |
多重特異性及び一価のigg分子の会合における鎖対形成の静電ステアリングにおけるバランスのとれた電荷分布
|
EP4329887A1
(en)
|
2021-04-28 |
2024-03-06 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
EP4334343A2
(en)
|
2021-05-06 |
2024-03-13 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
CA3218481A1
(en)
|
2021-06-14 |
2022-12-22 |
argenx BV |
Anti-il-9 antibodies and methods of use thereof
|
WO2022271987A1
(en)
|
2021-06-23 |
2022-12-29 |
TeneoFour, Inc. |
Anti-cd38 antibodies and epitopes of same
|
WO2022272018A1
(en)
|
2021-06-25 |
2022-12-29 |
Amgen Inc. |
Treatment of cardiovascular disease with trem-1 antigen binding proteins
|
KR20230004135A
(ko)
|
2021-06-30 |
2023-01-06 |
한미약품 주식회사 |
글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
|
WO2023004197A1
(en)
|
2021-07-23 |
2023-01-26 |
Teneoten, Inc. |
Heavy chain antibodies binding to hepatitis b surface antigen
|
AR126970A1
(es)
|
2021-09-02 |
2023-12-06 |
Djs Antibodies Ltd |
Polipétidos
|
WO2023043953A1
(en)
|
2021-09-16 |
2023-03-23 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
CA3232806A1
(en)
|
2021-09-30 |
2023-04-06 |
Seagen Inc. |
B7-h4 antibody-drug conjugates for the treatment of cancer
|
US20230192843A1
(en)
|
2021-10-14 |
2023-06-22 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
TW202342095A
(zh)
|
2021-11-05 |
2023-11-01 |
英商阿斯特捷利康英國股份有限公司 |
用於治療和預防covid—19之組成物
|
WO2023091968A1
(en)
|
2021-11-17 |
2023-05-25 |
Disc Medicine, Inc. |
Methods for treating anemia of kidney disease
|
TW202337904A
(zh)
|
2022-01-07 |
2023-10-01 |
美商壯生和壯生企業創新公司 |
IL-1β結合蛋白之材料及方法
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
WO2023173084A1
(en)
|
2022-03-11 |
2023-09-14 |
University Of Rochester |
Cyclopeptibodies and uses thereof
|
US20230381321A1
(en)
|
2022-03-17 |
2023-11-30 |
Seagan Inc., |
Camptothecin conjugates
|
WO2023209568A1
(en)
|
2022-04-26 |
2023-11-02 |
Novartis Ag |
Multispecific antibodies targeting il-13 and il-18
|
WO2023209177A1
(en)
|
2022-04-29 |
2023-11-02 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of using the same
|
US20240117021A1
(en)
|
2022-06-15 |
2024-04-11 |
Bioverativ Usa Inc. |
Anti-complement c1s antibody formulation
|
WO2023242371A1
(en)
|
2022-06-15 |
2023-12-21 |
argenx BV |
Ph-dependent hsa-binding molecules and methods of use
|
WO2023250507A1
(en)
|
2022-06-24 |
2023-12-28 |
Bioverativ Usa Inc. |
Methods for treating complement-mediated diseases
|
WO2024003376A1
(en)
|
2022-07-01 |
2024-01-04 |
Alk-Abelló A/S |
Displacers of ige-fceri
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
US20240108744A1
(en)
|
2022-07-27 |
2024-04-04 |
Mediboston Limited |
Auristatin derivatives and conjugates thereof
|
WO2024026358A1
(en)
|
2022-07-27 |
2024-02-01 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
WO2024026494A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Viral particles retargeted to transferrin receptor 1
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024026470A2
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:payload fusions and methods of use thereof
|
US11773160B1
(en)
|
2022-08-05 |
2023-10-03 |
Anaveon AG |
Immune-stimulating IL-2 fusion proteins
|
WO2024036139A2
(en)
|
2022-08-09 |
2024-02-15 |
Qlsf Biotherapeutics, Inc. |
Antibodies binding to clec12a
|
WO2024077044A1
(en)
|
2022-10-05 |
2024-04-11 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
US20240182561A1
(en)
|
2022-11-04 |
2024-06-06 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
US20240173426A1
(en)
|
2022-11-14 |
2024-05-30 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
US20240158515A1
(en)
|
2022-11-14 |
2024-05-16 |
Regeneron Pharmaceuticals, Inc. |
Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereof
|
WO2024129756A1
(en)
|
2022-12-13 |
2024-06-20 |
Seagen Inc. |
Site-specific engineered cysteine antibody drug conjugates
|
WO2024130158A1
(en)
|
2022-12-16 |
2024-06-20 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
|